STOCK TITAN
  1. Home
  2. Sec-filings
  3. AURA
  4. [Form 4] Aura Biosciences, Inc. Insider Trading Activity

Executive at Aura Biosciences (AURA) receives 14,858 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.

Aura Biosciences, Inc. reported that company officer Conor Kilroy received a grant of 14,858 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share of common stock.

The RSUs vest in two substantially equal annual installments beginning on July 15, 2027, conditioned on Kilroy’s continued service on each vesting date. Following this award, Kilroy directly holds a total of 232,693 shares of Aura Biosciences common stock.

Positive

  • None.

Negative

  • None.
Insider Kilroy Conor
Role See Remarks
Type Security Shares Price Value
Grant/Award Common Stock 14,858 $0.00 --
Holdings After Transaction: Common Stock — 232,693 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 14,858 shares Restricted stock unit award to Conor Kilroy
Holdings after transaction 232,693 shares Common stock directly held by Conor Kilroy after grant
Vesting start date July 15, 2027 First of two substantially equal annual RSU vesting installments
Grant price per share $0.0000 RSU award granted at no cash purchase price
restricted stock unit ("RSU") financial
"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."
2021 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."
vest in two substantially equal annual installments financial
"These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kilroy Conor
(Last)(First)(Middle)
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET
(Street)
BOSTON MASSACHUSETTS 02135
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026A14,858(1)A$0232,693D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in two substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
Remarks:
Chief Legal Officer and Secretary
/s/ Conor Kilroy07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aura Biosciences (AURA) report for Conor Kilroy?

Aura Biosciences reported that officer Conor Kilroy received a grant of 14,858 restricted stock units, each representing one share of common stock. The award was made at no cash cost and increases his direct holdings to 232,693 common shares after the grant.

How many Aura Biosciences (AURA) shares did Conor Kilroy hold after the RSU grant?

After the RSU grant, Conor Kilroy directly held 232,693 shares of Aura Biosciences common stock. This total includes the 14,858 shares underlying the newly granted restricted stock units, which will convert into shares as they vest over the specified schedule.

What are the vesting terms of Conor Kilroy’s RSU award at Aura Biosciences (AURA)?

The RSU award vests in two substantially equal annual installments beginning on July 15, 2027. Vesting is conditioned on Kilroy’s continued service with Aura Biosciences as of each vesting date, meaning he receives the underlying shares only as each installment vests.

Did Conor Kilroy pay a purchase price for the Aura Biosciences (AURA) RSUs?

No cash purchase price was paid for the RSUs; the Form 4 lists the price per share as 0.0000. The award represents equity-based compensation granted under Aura Biosciences’ 2021 Stock Option and Incentive Plan, rather than an open-market stock purchase by the officer.

Under which plan were Conor Kilroy’s Aura Biosciences (AURA) RSUs granted?

The RSUs were granted under Aura Biosciences’ 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of common stock, subject to the plan’s terms and the vesting conditions tied to Kilroy’s continued service with the company.